H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Patrick Trucchio has given his Buy rating due to a combination of factors including Sangamo Biosciences’ promising near-term strategic milestones and potential for significant value creation. The company is approaching pivotal milestones such as the Phase 2 data readout from the STAAR trial in Fabry disease, which is expected by the end of the second quarter of 2025. This readout could significantly reduce risks ahead of a planned Biologics License Application submission in the first quarter of 2026 and a potential first-in-class gene therapy approval in the second half of 2026.
Additionally, Sangamo’s ST-503 and ST-506 programs are on track to enter clinical development in 2025 and 2026, respectively, with preliminary data expected in the fourth quarter of 2026. The company’s platforms, including STAC-BBB and MINT, are gaining momentum with high-value partnerships and promising preclinical data. These developments, along with recent financings extending the company’s financial runway into late third quarter of 2025, align Sangamo’s pipeline and platform to potentially unlock significant upside from current levels.
Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, Alnylam Pharma, and Altimmune. According to TipRanks, Trucchio has an average return of -1.5% and a 34.98% success rate on recommended stocks.
In another report released on May 14, Barclays also maintained a Buy rating on the stock with a $5.00 price target.